# Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

> **NCT00496821** · PHASE2 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 88 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** ALN-RSV01

## Key facts

- **NCT ID:** NCT00496821
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2007-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00496821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00496821, "Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00496821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*